More than half of infants protected by maternal RSV vaccine, nirsevimab, or both

In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research published in the Sep. 26 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup